From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

[1]  I. Hirsch,et al.  Correction to: The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[2]  K. Cusi,et al.  Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[3]  K. Cusi,et al.  Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. , 2019, The Journal of endocrinology.

[4]  K. Cusi.  Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes , 2019, Hepatology.

[5]  G. Qin,et al.  Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[6]  A. Astrup,et al.  Interaction between hormone-sensitive lipase and ChREBP in fat cells controls insulin sensitivity , 2018, Nature Metabolism.

[7]  N. Lundbom,et al.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study , 2018, Diabetes, obesity & metabolism.

[8]  K. Cusi,et al.  Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial , 2018, Journal of diabetes.

[9]  S. Mudaliar,et al.  Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes , 2019, Diabetes, obesity & metabolism.

[10]  4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[11]  R. Aronson,et al.  SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. , 2018, Diabetes & metabolism.

[12]  M. Moriguchi,et al.  Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis , 2018, Diabetes, metabolic syndrome and obesity : targets and therapy.

[13]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[14]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[15]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[16]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[17]  P. O'Neil,et al.  Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial , 2018, The Lancet.

[18]  B. Zinman,et al.  Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial , 2018, Diabetologia.

[19]  F. Rutten,et al.  The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: A systematic review and meta-analysis , 2018, Diabetes & vascular disease research.

[20]  N. Sattar,et al.  Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[21]  S. Inzucchi,et al.  Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits , 2018, Diabetologia.

[22]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[23]  Shahinul Alam,et al.  Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial , 2018, Hepatic medicine : evidence and research.

[24]  Marju Orho-Melander,et al.  Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.

[25]  R. Pratley,et al.  Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. , 2018, The lancet. Diabetes & endocrinology.

[26]  A. Scheen.  The safety of gliptins : updated data in 2018 , 2018, Expert opinion on drug safety.

[27]  N. Fushimi,et al.  Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study , 2018, Diabetes, obesity & metabolism.

[28]  M. Nauck,et al.  Incretin hormones: Their role in health and disease , 2018, Diabetes, obesity & metabolism.

[29]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis , 2018, Diabetes Care.

[30]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[31]  K. Cusi,et al.  Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  Tommi Suvitaival,et al.  Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. , 2018, Metabolism: clinical and experimental.

[33]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[34]  A. Gastaldelli.  Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? , 2017, Clinical science.

[35]  B. Hoogwerf,et al.  Non‐alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[36]  S. Trattnig,et al.  Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients , 2017, European journal of clinical investigation.

[37]  T. Fujimori,et al.  The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin , 2017, Internal medicine.

[38]  D. Drucker,et al.  Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors , 2017, Circulation.

[39]  P. Iozzo,et al.  Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes , 2017, Diabetes Care.

[40]  Yasushi Tanaka,et al.  Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes , 2017, Expert opinion on pharmacotherapy.

[41]  C. Postic,et al.  Sweet Sixteenth for ChREBP: Established Roles and Future Goals. , 2017, Cell metabolism.

[42]  Dalong Zhu,et al.  Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease , 2017, Journal of diabetes.

[43]  M. Roden,et al.  Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. , 2017, Clinical science.

[44]  F. Schick,et al.  Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. , 2017, Cell metabolism.

[45]  M. Noda,et al.  Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial , 2017, Diabetes Care.

[46]  C. Cohrs,et al.  Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis , 2017, Molecular metabolism.

[47]  S. Ishihara,et al.  Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study , 2017, Current therapeutic research, clinical and experimental.

[48]  K. Clément,et al.  Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study , 2017, Diabetologia.

[49]  K. Kalinov,et al.  Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis , 2017, Diabetes Therapy.

[50]  B. Finck,et al.  PPARs and nonalcoholic fatty liver disease. , 2017, Biochimie.

[51]  Jonathan C. Cohen,et al.  Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by Multiple Loci , 2017, Nature Genetics.

[52]  K. Cusi,et al.  Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.

[53]  K. Higuchi,et al.  A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. , 2017, International journal of molecular medicine.

[54]  K. Cusi,et al.  Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies , 2017, Trends in Endocrinology & Metabolism.

[55]  H. Miyoshi,et al.  Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. , 2017, Endocrine journal.

[56]  T. Yoshimoto,et al.  Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. , 2017, Endocrine journal.

[57]  Koichi Yabiku,et al.  Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. , 2017, Clinical therapeutics.

[58]  A. Tura,et al.  Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß‐cell function in non‐diabetic, morbidly obese patients , 2017, Diabetes, obesity & metabolism.

[59]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[60]  In-kyu Lee,et al.  Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. , 2017, Canadian journal of physiology and pharmacology.

[61]  Mi-kyung Kim,et al.  Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models , 2017, Archives of pharmacal research.

[62]  C. McKenzie,et al.  Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. , 2017, World journal of gastroenterology.

[63]  Amalia Gastaldelli,et al.  Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study , 2017, Diabetes.

[64]  H. Kanehara,et al.  The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus , 2017, Diabetology International.

[65]  K. Furie,et al.  Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. , 2016, The Journal of clinical endocrinology and metabolism.

[66]  E. Paschetta,et al.  Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges , 2016, Hepatology.

[67]  O. Chevallier,et al.  Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study , 2016, The Journal of clinical endocrinology and metabolism.

[68]  N. Inagaki,et al.  Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials , 2017, Journal of Gastroenterology.

[69]  B. Staels,et al.  PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD , 2017, Nature Reviews Endocrinology.

[70]  Inês Barroso,et al.  Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance , 2016, Nature Genetics.

[71]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. , 2016, Endocrinology and metabolism clinics of North America.

[72]  A. Chang,et al.  Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[73]  H. Soni,et al.  Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity. , 2016, Medical hypotheses.

[74]  P. Pouwels,et al.  Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial , 2016, Diabetologia.

[75]  P. Iozzo,et al.  Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study , 2016, Hepatology.

[76]  C. Viscoli,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[77]  Qin He,et al.  GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. , 2016, Biochemical and biophysical research communications.

[78]  D. Brenner,et al.  Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. , 2016, Journal of hepatology.

[79]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[80]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[81]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[82]  K. Cusi,et al.  Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus , 2016, Clinical Diabetes and Endocrinology.

[83]  Xiaochen Wang,et al.  Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[84]  P. Hytiroglou,et al.  Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. , 2016, Diabetes research and clinical practice.

[85]  M. Yoneda,et al.  Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. , 2016, World journal of gastroenterology.

[86]  T. Ohki,et al.  Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inh , 2016, Clinical Drug Investigation.

[87]  D. Tanné,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[88]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[89]  E. Ruppin,et al.  Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease , 2016, Nature Communications.

[90]  Lawrence A Leiter,et al.  Effect of canagliflozin on liver function tests in patients with type 2 diabetes. , 2016, Diabetes & metabolism.

[91]  G. Marchesini,et al.  Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? , 2016, Journal of hepatology.

[92]  S. Gough,et al.  Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis , 2016, Journal of hepatology.

[93]  T. Vilsbøll,et al.  Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia , 2016, Journal of internal medicine.

[94]  A. Gastaldelli,et al.  Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease , 2016, Hepatology.

[95]  M. Shimizu,et al.  The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice , 2015, International journal of molecular sciences.

[96]  H. J. Yoo,et al.  A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression. , 2015, Biochemical pharmacology.

[97]  A. Gastaldelli,et al.  The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis , 2015, Nutrients.

[98]  E. Barrett-Connor,et al.  Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study , 2015, The lancet. Diabetes & endocrinology.

[99]  A. Srinivasan,et al.  Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial. , 2015, Diabetes research and clinical practice.

[100]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes , 2015, PloS one.

[101]  H. Mitsui,et al.  Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury , 2015, SpringerPlus.

[102]  T. Sasaoka,et al.  Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. , 2015, Diabetes research and clinical practice.

[103]  J. D. De Guise,et al.  Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial , 2015, Diabetes Care.

[104]  Hirokazu Takahashi,et al.  Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[105]  M. Orho-Melander,et al.  Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.

[106]  S. Klein,et al.  Metabolically normal obese people are protected from adverse effects following weight gain. , 2015, The Journal of clinical investigation.

[107]  J. Borén,et al.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.

[108]  J. Sowers,et al.  Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function , 2015, Diabetes.

[109]  Roy Taylor,et al.  Effect of Vildagliptin on Hepatic Steatosis , 2015, The Journal of clinical endocrinology and metabolism.

[110]  T. Vilsbøll,et al.  Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes , 2014, BMJ Open.

[111]  M. Mori,et al.  MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. , 2014, World journal of gastroenterology.

[112]  P. Munroe,et al.  Genetic Evidence for a Normal-Weight “Metabolically Obese” Phenotype Linking Insulin Resistance, Hypertension, Coronary Artery Disease, and Type 2 Diabetes , 2014, Diabetes.

[113]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[114]  J. Weng,et al.  SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis , 2014, Diabetes.

[115]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[116]  K. Nadeau,et al.  Adipose tissue insulin resistance in adolescents with and without type 2 diabetes , 2014, Pediatric obesity.

[117]  I. Kanazawa,et al.  DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus , 2014, Medical science monitor : international medical journal of experimental and clinical research.

[118]  M. Bergman.  Global Health Perspectives in Prediabetes and Diabetes Prevention , 2014 .

[119]  E. Ferrannini,et al.  Pathophysiology of Prediabetes: Role of Lipotoxicity? , 2014 .

[120]  M. Hao,et al.  Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes , 2014, Diabetes/metabolism research and reviews.

[121]  Ming Li,et al.  Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes , 2014, Acta Diabetologica.

[122]  In-kyu Lee,et al.  Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. , 2014, Diabetes research and clinical practice.

[123]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[124]  K. Cusi,et al.  Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis , 2014, Hepatology.

[125]  T. Hansen,et al.  Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond , 2014, Diabetologia.

[126]  K. Kotoh,et al.  Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. , 2014, World journal of gastroenterology.

[127]  S. Gough,et al.  Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis , 2014, Diabetes, obesity & metabolism.

[128]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[129]  M. Imamura,et al.  Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. , 2014, Hepato-gastroenterology.

[130]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[131]  T. Kakimoto,et al.  The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. , 2014, European journal of pharmacology.

[132]  M. Fujii,et al.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis , 2014, Medical Molecular Morphology.

[133]  L. Vergani,et al.  Effects of binge ethanol on lipid homeostasis and oxidative stress in a rat model of nonalcoholic fatty liver disease , 2014, Journal of Physiology and Biochemistry.

[134]  Kassem M. Makki,et al.  Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines , 2013, ISRN inflammation.

[135]  V. Mohan,et al.  Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population. , 2013, Gene.

[136]  Xin-chun Yang,et al.  Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. , 2013, Arquivos brasileiros de endocrinologia e metabologia.

[137]  Yoshiyuki Suzuki,et al.  Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[138]  Q. Anstee,et al.  The genetics of NAFLD , 2013, Nature Reviews Gastroenterology &Hepatology.

[139]  G. Bray,et al.  Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk , 2013, Diabetes Care.

[140]  Damjana Rozman,et al.  Genomic aspects of NAFLD pathogenesis. , 2013, Genomics.

[141]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[142]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[143]  K. Cusi,et al.  The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus , 2013, Current Diabetes Reports.

[144]  G. Musso,et al.  Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism , 2013, Diabetes.

[145]  S. Gough,et al.  Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program , 2013, Alimentary pharmacology & therapeutics.

[146]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[147]  C. Streutker,et al.  GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. , 2013, Endocrinology.

[148]  Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis , 2013, Molecular Biology Reports.

[149]  M. Pirmohamed,et al.  Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists , 2012, PloS one.

[150]  M. Omata,et al.  The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone , 2012, TheScientificWorldJournal.

[151]  D. Stiller,et al.  Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity , 2012, PloS one.

[152]  S. Summers,et al.  A ceramide-centric view of insulin resistance. , 2012, Cell metabolism.

[153]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[154]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[155]  S. Friedman,et al.  Glucokinase links Krüppel‐like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease , 2012, Hepatology.

[156]  J. Kullberg,et al.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.

[157]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[158]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[159]  E. Ferrannini,et al.  Direct effect of GLP-1 infusion on endogenous glucose production in humans , 2012, Diabetologia.

[160]  S. Burgess,et al.  Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. , 2011, Cell metabolism.

[161]  Y. Terauchi,et al.  Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. , 2011, Hepato-gastroenterology.

[162]  M. Vivarelli,et al.  Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[163]  R. Muthupillai,et al.  Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial , 2011, Diabetologia.

[164]  F. Anania,et al.  GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy , 2011, PloS one.

[165]  A. Gastaldelli.  Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 2011, Diabetes research and clinical practice.

[166]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[167]  N. Lundbom,et al.  Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. , 2011, The American journal of clinical nutrition.

[168]  Z. Halpern,et al.  Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. , 2011, Journal of hepatology.

[169]  G. Boden.  Obesity, insulin resistance and free fatty acids , 2011, Current opinion in endocrinology, diabetes, and obesity.

[170]  Y. Terauchi,et al.  Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice , 2011, Diabetes.

[171]  R. DeFronzo,et al.  Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. , 2011, The Journal of clinical endocrinology and metabolism.

[172]  J. Gagliardino,et al.  Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. , 2011, Clinical science.

[173]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[174]  J. Ntambi,et al.  Genetic control of de novo lipogenesis: role in diet-induced obesity , 2010, Critical reviews in biochemistry and molecular biology.

[175]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[176]  R. DeFronzo.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 , 2010, Diabetologia.

[177]  M. Trauner,et al.  Fatty liver and lipotoxicity. , 2010, Biochimica et biophysica acta.

[178]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[179]  S. Prato.  Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies , 2009 .

[180]  D. Matthews,et al.  Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue , 2009, Diabetes, obesity & metabolism.

[181]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[182]  F. Schick,et al.  Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene , 2009, Diabetes.

[183]  C. Nolan,et al.  Lipotoxicity: Why do saturated fatty acids cause and monounsaturates protect against it? , 2009, Journal of gastroenterology and hepatology.

[184]  Jeroen J. Bax,et al.  Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus , 2009, Circulation.

[185]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[186]  G. Pacini,et al.  Transcription factor 7–like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH , 2009, Hepatology.

[187]  M. Orešič,et al.  Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver , 2009, Diabetes.

[188]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[189]  U. Kintscher.  Pharmacological differences of glitazones: does peroxisome proliferator-activated receptor-alpha activation make the difference? , 2008, Journal of the American College of Cardiology.

[190]  O. Hamdy,et al.  The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. , 2008, Journal of the American College of Cardiology.

[191]  B. Balkau,et al.  The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population , 2008, Diabetes.

[192]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[193]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[194]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[195]  G. Tell,et al.  Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. , 2008, Trends in molecular medicine.

[196]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[197]  Peter Almgren,et al.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. , 2007, The Journal of clinical investigation.

[198]  J. Eriksson.  Metabolic stress in insulin's target cells leads to ROS accumulation – A hypothetical common pathway causing insulin resistance , 2007, FEBS letters.

[199]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[200]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[201]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[202]  Y. Miyazaki,et al.  The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[203]  H. Stefánsson,et al.  Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes , 2006, Nature Genetics.

[204]  Peter Nowotny,et al.  Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. , 2006, Diabetes.

[205]  I. Leclercq,et al.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. , 2005, Gastroenterology.

[206]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[207]  R. DeFronzo,et al.  Dose-response effect of elevated plasma free fatty acid on insulin signaling. , 2005, Diabetes.

[208]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[209]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[210]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[211]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[212]  Peter Almgren,et al.  Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. , 2005, Diabetes.

[213]  Y. Miyazaki,et al.  Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. , 2004, The Journal of clinical endocrinology and metabolism.

[214]  R. DeFronzo,et al.  A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.

[215]  D. D’Alessio,et al.  Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. , 2003, American journal of physiology. Endocrinology and metabolism.

[216]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[217]  M. Matsuda,et al.  Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study , 2003, Diabetologia.

[218]  N. Ruderman,et al.  Lipid-Induced Insulin Resistance in Human Muscle Is Associated With Changes in Diacylglycerol, Protein Kinase C, and IκB-α , 2002 .

[219]  J. Rosenstock,et al.  EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY , 2002, International journal of clinical practice.

[220]  M. Matsuda,et al.  Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.

[221]  E. Ferrannini,et al.  Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. , 2001, Diabetes.

[222]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[223]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[224]  E. Ferrannini,et al.  Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.

[225]  A. Cherrington,et al.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. , 1999, Diabetes.

[226]  G. Lewis,et al.  Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats. , 1997, Journal of lipid research.

[227]  G. Gibbons,et al.  VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin. , 1995, The American journal of physiology.

[228]  G. Gibbons,et al.  Decreased sensitivity to the inhibitory effect of insulin on the secretion of very-low-density lipoprotein in cultured hepatocytes from fructose-fed rats. , 1995, Metabolism: clinical and experimental.

[229]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[230]  B V Howard,et al.  Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. , 1988, The New England journal of medicine.